Skip to main content

Advertisement

SpringerLink
Log in

Interstitial Lung Disease and ANCA-Associated Vasculitis

  • Vasculitis (L Barra, Section Editor)
  • Published:
Current Treatment Options in Rheumatology Aims and scope Submit manuscript

Abstract

Purpose of the review

Interstitial lung disease (ILD) in the antineutrophil cytoplasm autoantibodies (ANCA)-associated vasculitides (AAV) is increasingly recognized. The main pattern is that of usual interstitial pneumonia (UIP) mostly occurring in patients who are positive for anti-myeloperoxidase autoantibodies (MPO-ANCA). We touch on some pathogenetic hypothesis concerning how ILD may develop within the AAV, present specific diagnostic items in the context of ILD, discuss the role of imaging in ILD, canvass different scenarios regarding the interplay between ANCA targeting myeloperoxidase (MPO-ANCA) and ILD, and discourse over the current, still not evidence-based treatment for this condition, posing several questions deserving consideration for the design of studies focusing on this unmet need.

Recent findings

An increasing number of reports describe patients with antedating ILD to other AAV features. Emerging imaging data is helpful concerning specific areas of lung involvement in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). The approval of specific antifibrotic treatments in lung disease may be helpful in patients with ILD and AAV.

Summary

Different clinical scenarios concerning ILD, MPO-ANCA, and MPA exist. Clear data on each of these conditions concerning physiopathology, clinical features, and treatment is lacking, but increasing attention is being given to them that may lead to promissory developments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. • Alba MA, Flores-Suárez LF, Henderson AG, Hong X, Hu P, Nachman PH, et al. Interstitial lung disease in ANCA vasculitis. Autoimmun Rev. 2017;16:722–9. https://doi.org/10.1016/j.autrev.2017.05.008 A recent comprehensive review on the subject presenting and summarizing information on the matter.

  2. Birnbaum J, Danoff S, Askin FB, Stone JH. Microscopic polyangiitis presenting as a “pulmonary-muscle” syndrome: is subclinical alveolar hemorrhage the mechanism of pulmonary fibrosis? Arthritis Rheum. 2007;56:2065–71.

    Article  PubMed  Google Scholar 

  3. Pineton de Chambrun M, Nunes H, Brochériou I, Hertig A. Idiopathic lung fibrosis and anti myeloperoxidase glomerulonephritis: the tree that hides the forest. BMC Pulm Med. 2015;15:130. https://doi.org/10.1186/s12890-015-0129-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Travis WD, Hoffman GS, Leavitt RY, Pass HI, Fauci AS. Surgical pathology of the lung in Wegener’s granulomatosis. Review of 87 open lung biopsies from 67 patients. Am J Surg Pathol. 1991;15:315–33.

    Article  CAS  PubMed  Google Scholar 

  5. Schnabel A, Reuter M, Csernok E, Richter C, Gross WL. Subclinical alveolar bleeding in pulmonary vasculitides: correlation with indices of disease activity. Eur Respir J. 1999;14:118–24.

    Article  CAS  PubMed  Google Scholar 

  6. Fernandez Casares M, Gonzalez A, Fielli M, Caputo F, Bottinelli Y, Zamboni M. Microscopic polyangiitis associated with pulmonary fibrosis. Clin Rheumatol. 2015;34:1273–7. https://doi.org/10.1007/s10067-014-2676-1.

    Article  PubMed  Google Scholar 

  7. Guilpain P, Chéreau C, Goulvestre C, Servettaz A, Montani D, Tamas N, et al. The oxidation induced by antimyeloperoxidase antibodies triggers fibrosis in microscopic polyangiitis. Eur Respir J. 2011;37:1503–13. https://doi.org/10.1183/09031936.00148409.

    Article  CAS  PubMed  Google Scholar 

  8. Ando Y, Okada F, Matsumoto S, Mori H. Thoracic manifestation of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA)-related disease. CT findings in 51 patients. J Comput Assist Tomogr. 2004;28:710–6.

    Article  PubMed  Google Scholar 

  9. King TE Jr, Pardo A, Selman M. Idiopathic lung fibrosis. Lancet. 2011;378:1949–61. https://doi.org/10.1016/S0140-6736(11)60052-4.

    Article  PubMed  Google Scholar 

  10. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2002;165:277–304.

    Article  Google Scholar 

  11. Foucher P, Heeringa P, Petersen AH, Huitema MG, Brouwer E, Tervaert JW, et al. Antimyeloperoxidase-associated lung disease. An experimental model. Am J Respir Crit Care Med. 1999;160:987–94.

    Article  CAS  PubMed  Google Scholar 

  12. Lucattelli M, Bartalesi B, Cavarra E, Fineschi S, Lunghi B, Martorana PA. Is neutrophil elastase the missing link between emphysema and fibrosis? Evidence from two mouse models. Respir Res. 2005;6:83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Gehrig S, Duerr J, Weitnauer M, Wagner CJ, Graeber SY, Schatterny J, et al. Lack of neutrophil elastase reduces inflammation, mucus hypersecretion, and emphysema, but not mucus obstruction, in mice with cystic fibrosis-like lung disease. Am J Respir Crit Care Med. 2014;189:1082–92. https://doi.org/10.1164/rccm.201311-1932OC.

    Article  PubMed  Google Scholar 

  14. Vancheri C, Gauldie J, Bienenstock J, Cox G, Scicchitano R, Stanisz A, et al. Human lung fibroblast-derived granulocyte-macrophage colony stimulating factor (GM-CSF) mediates eosinophil survival in vitro. Am J Respir Cell Mol Biol. 1989;1:289–95.

    Article  CAS  PubMed  Google Scholar 

  15. Peterson MW, Monick M, Hunninghake GW. Prognostic role of eosinophils in pulmonary fibrosis. Chest. 1987;92:51–6.

    Article  CAS  PubMed  Google Scholar 

  16. Mack M. Inflammation and fibrosis. Matrix Biol. 2018;68-69:106–21. https://doi.org/10.1016/j.matbio.2017.11.010.

    Article  CAS  PubMed  Google Scholar 

  17. • Yoshida M, Yamada M, Sudo Y, Kojima T, Tomiyasu T, Yoshikawa N. Myeloperoxidase anti-neutrophil cytoplasmic antibody affinity is associated with the formation of neutrophil extracellular traps in the kidney and vasculitis activity in myeloperoxidase anti-neutrophil cytoplasmic antibody-associated microscopic polyangiitis. Nephrology (Carlton). 2016;21:624–9. https://doi.org/10.1111/nep.12736 A relevant study showing that not only the type of autoantibody, but also its biological properties, influence different responses or ellicit distinctively biological phenomenae.

  18. Chrysanthopoulou A, Mitroulis I, Apostolidou E, Arelaki S, Mikroulis D, Konstantinidis T, et al. Neutrophil extracellular traps promote differentiation and function of fibroblasts. J Pathol. 2014;233:294–307. https://doi.org/10.1002/path.4359.

    Article  CAS  PubMed  Google Scholar 

  19. Gindre D, Peyrol S, Raccurt M, Sommer P, Loire R, Grimaud JA, et al. Fibrosing vasculitis in Wegener’s granulomatosis: ultrastructural and immunohistochemical analysis of the vascular lesions. Virchows Arch. 1995;427:385–93.

    Article  CAS  PubMed  Google Scholar 

  20. Churg A, Zay K, Shay S, Xie C, Shapiro SD, Hendricks R, et al. Acute cigarette smoke-induced connective tissue breakdown requires both neutrophils and macrophage metalloelastase in mice. Am J Respir Cell Mol Biol. 2002;27:368–74.

    Article  CAS  PubMed  Google Scholar 

  21. Nemoto M, Noma S, Otsuki A, Nakashima K, Honma K, Johkoh T, et al. Combined pulmonary fibrosis and emphysema with anti-myeloperoxidase antineutrophil cytoplasmic antibody positivity that resolved upon smoking cessation. Respir Med Case Rep. 2018;25:165–9. https://doi.org/10.1016/j.rmcr.2018.08.022.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Fidler L, Sitzer N, Shapera S, Shah PS. Treatment of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Chest. 2018;153:1405–15. https://doi.org/10.1016/j.chest.2018.03.008.

    Article  PubMed  Google Scholar 

  23. Bédard Méthot D, Leblanc É, Lacasse Y. Meta-analysis of gastroesophageal reflux disease and idiopathic pulmonary fibrosis. Chest. 2018;155:33–43. https://doi.org/10.1016/j.chest.2018.07.038.

    Article  PubMed  Google Scholar 

  24. Nakazawa D, Tomaru U, Suzuki A, Masuda S, Hasegawa R, Kobayashi T, et al. Abnormal conformation and impaired degradation of propylthiouracil-induced neutrophil extracellular traps: implications of disordered neutrophil extracellular traps in a rat model of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012;64:3779–87. https://doi.org/10.1002/art.34619.

    Article  CAS  PubMed  Google Scholar 

  25. Flores-Suárez LF. Limited pulmonary MPA, a new MPA entity? A rheumatologist’s perspective. Clin Exp Nephrol. 2013;17:672–5.

    Article  PubMed  Google Scholar 

  26. Mark EJ, Matsubara O, Tan-Liu NS, Fienberg R. The pulmonary biopsy in the early diagnosis of Wegener’s (pathergic) granulomatosis: a study based on 35 open lung biopsies. Hum Pathol. 1988;19:1065–71.

    Article  CAS  PubMed  Google Scholar 

  27. Yoshikawa Y, Watanabe T. Pulmonary lesions in Wegener’s granulomatosis: a clinicopathologic study of 22 autopsy cases. Hum Pathol. 1986;17:401–10.

    Article  CAS  PubMed  Google Scholar 

  28. • Ishizaki J, Takemori A, Suemori K, Matsumoto T, Akita Y, Sada KE, et al. Targeted proteomics reveals promising biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Res Ther. 2017;19:218. https://doi.org/10.1186/s13075-017-1429-3 Using advanced techniques for identification of potential useful biomarkers both in active and remission patients with AAV, the researchers found that tenascin C associated with subjects who had lung involvement.

  29. Tsicopoulos A, Chang Y, Ait Yahia S, de Nadai P, Chenivesse C. Role of CCL18 in asthma and lung immunity. Clin Exp Allergy. 2013;43:716–22. https://doi.org/10.1111/cea.12065.

    Article  CAS  PubMed  Google Scholar 

  30. Nozu T, Kondo M, Suzuku K, Tamaoki J, Nagai A. A comparison of the clinical features of ANCA-positive and ANCA-negative idiopathic pulmonary fibrosis patients. Respiration. 2009;77:407–15. https://doi.org/10.1159/000183754.

    Article  CAS  PubMed  Google Scholar 

  31. Homma S, Matsushita H, Nakata K. Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides. Respirology. 2004;9:190–6.

    Article  PubMed  Google Scholar 

  32. Yu AP, Chang JX, Liu YJ, Qu QR. Computed tomography image analysis before and after treatment of anti-neutrophil cytoplasmic antibody-associated pulmonary interstitial fibrosis in 8 patients. Clin Ther. 2014;36:2064–71. https://doi.org/10.1016/j.clinthera.2014.09.025.

    Article  PubMed  Google Scholar 

  33. •• Hosoda C, Baba T, Hagiwara E, Ito H, Matsuo N, Kitamura H, et al. Clinical features of usual interstitial pneumonia with anti-neutrophil cytoplasmic antibody in comparison with idiopathic pulmonary fibrosis. Respirology. 2016;21:920–6. https://doi.org/10.1111/resp.12763 A retrospective study that showed some imaging and histopathological differences between patients with ILF and those with LF associated witn MPO-ANCA.

  34. Flores-Suárez LF, Ruiz N, Saldarriaga Rivera LM, Pensado L. Reduced survival in microscopic polyangiits patients with pulmonary fibrosis in a respiratory referral centre. Clin Rheumatol. 2015;34:1653–4. https://doi.org/10.1007/s10067-015-2967-1.

    Article  PubMed  Google Scholar 

  35. Ravaglia C, Wells AU, Tomassetti S, Gurioli C, Gurioli C, Dubini A, et al. Diagnostic yield and risk-benefit analysis of trans-bronchial lung cryobiopsy in diffuse parenchymal lung diseases: a large cohort on 699 patients. BMC Pulm Med. 2019;19:16. https://doi.org/10.1186/s12890-019-0780-3.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Wälscher J, Groß B, Eberhardt R, Heussel CP, Eichinger M, Warth A, et al. Transbronchial cryobiopsies for diagnosing interstitial lung diseases: real-life experience from a tertiary referral center for interstitial lung disease. Respiration. 2018;14:1–7. https://doi.org/10.1159/000493428.

    Article  Google Scholar 

  37. •• Romagnoli M, Colby TV, Berthet JP, Gamez AS, Mallet JP, Serre I, et al. Poor conocrdance between sequential transbronchial lung cryobiopsy and surgical lung biopsy in the diagnosis of diffuse interstitial lung diseases. Am J Resp Crit Care Med. 2019. https://doi.org/10.1164/rccm.201810-1947OC An important study showing that the lung biopsy obtainment technique may infuence therapeutical, multidisciplinary decisions. Also, that this issue is still unresolved in the complex scneario of interstitial lung diseases.

  38. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic lung fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Resp Crit Care Med. 2018;198:e44–68. https://doi.org/10.1164/rccm.201807-1255ST.

    Article  PubMed  Google Scholar 

  39. • Martinez FJ, Chisholm A, Collard HR, Flaherty KR, Myers J, Taghu G, et al. The diagnosis of idiopathic pulmonary fibrosis: current and future approaches. Lancet Respir Med. 2017;5:61–71. https://doi.org/10.1016/S2213-2600(16)30325-3 A thorough review with discussion about uncertanties and controversial issues regarding ILF.

  40. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733–48. https://doi.org/10.1164/rccm.201308-1483ST.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Hervier B, Pagnoux C, Agard C, Haroche J, Amoura Z, Guillevin L, et al. Pulmonary fibrosis associated with ANCA-positive vasculitides. Retrospective study of 12 cases and review of the literature. Ann Rheum Dis. 2009;68:404–7. https://doi.org/10.1136/ard.2008.096131.

    Article  CAS  PubMed  Google Scholar 

  42. Tzelepis GE, Kokosi M, Tzioufas A, Toya SP, Boki KA, Zormpala A, et al. Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis. Eur Respir J. 2010;36:116–21. https://doi.org/10.1183/09031936.00110109.

    Article  CAS  PubMed  Google Scholar 

  43. Arulkumaran N, Periselneris N, Gaskin G, Strickland N, Ind PW, Pusey CD, et al. Interstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort study. Rheumatology. 2011;50:2035–43. https://doi.org/10.1093/rheumatology/ker236.

    Article  PubMed  Google Scholar 

  44. Comarmond C, Crestani B, Tazi A, Hervier B, Adam-Marchand S, Nunes H, et al. Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature. Medicine (Baltimore). 2014;93:340–9. https://doi.org/10.1097/MD.0000000000000217.

    Article  CAS  Google Scholar 

  45. • Yamagata M, Ikeda K, Tsushima K, Iesato K, Abe M, Ito T, et al. Prevalence and responsiveness to treatment of lung abnormalities on chest computed tomography in patients with microscopic polyangiitis: a multicenter, longitudinal, retrospective study of one hundred fifty consecutive hospital-based Japanese patients. Arthritis Rheumatol. 2016;68:713–23. https://doi.org/10.1002/art.39475 A large study with prospectively collected information on chest imaging, detailing the imaging findings in MPA. It confirms that an UIP pattern associates with shorter survival. Also, it shows the differences seen after treatment for MPA.

  46. Huang H, Wang YX, Jiang CG, Liu J, Li J, Xu K, et al. A retrospective study of microscopic polyangiitis patients presenting with pulmonary fibrosis in China. BMC Pulm Med. 2014;14:8. https://doi.org/10.1186/1471-2466-14-8.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Tzouvelekis A, Zacharis G, Oikonomou A, Koulelidis A, Steiropoulos P, Froudarakis M, et al. Combined pulmonary fibrosis and emphysema associated with microscopic polyangiitis. Eur Respir J. 2012;40:505–7. https://doi.org/10.1183/09031936.00216311.

    Article  PubMed  Google Scholar 

  48. Gocho K, Sugino K, Sato K, Hasegawa C, Uekusa T, Homma S. Microscopic polyangiitis preceded by combined pulmonary fibrosis and emphysema. Respir Med Case Rep. 2015;15:128–32. https://doi.org/10.1016/j.rmcr.2015.02.004.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Eschun GM, Mink SN, Sharma S. Pulmonary interstitial fibrosis as a presenting manifestation in perinuclear antineutrophilic cytoplasmic antibody microscopic polyangiitis. Chest. 2003;123:297–301.

    Article  PubMed  Google Scholar 

  50. Yamada H. ANCA: associated lung fibrosis. Semin Respir Crit Care Med. 2011;32:322–7. https://doi.org/10.1055/s-0031-1279828.

    Article  PubMed  Google Scholar 

  51. Foulon G, Delaval P, Valeyre D, Wallaert B, Debray MP, Brauner M, et al. ANCA-associated lung fibrosis: analysis of 17 patients. Respir Med. 2008;102:1392–8. https://doi.org/10.1016/j.rmed.2008.04.023.

    Article  PubMed  Google Scholar 

  52. Tanaka T, Otani K, Egashira R, Kashima Y, Taniguchi H, Kondoh Y, et al. Interstitial pneumonia associated with MPO-ANCA: clinicopathological features of nine patients. Respir Med. 2012;106:1765–70. https://doi.org/10.1016/j.rmed.2012.08.024.

    Article  PubMed  Google Scholar 

  53. Kono M, Nakamura Y, Enomoto N, Hashimoto D, Fujisawa T, Inui N, et al. Usual interstitial pneumonia preceding collagen vascular disease: a retrospective case control study of patients initially diagnosed with idiopathic pulmonary fibrosis. PLoS One. 2014;9:e94775. https://doi.org/10.1371/journal.pone.0094775.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Ando M, Miyazaki E, Ishii T, Mukai Y, Yamasue M, Fujisaki H, et al. Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis. Respir Med. 2013;107:608–15. https://doi.org/10.1016/j.rmed.2013.01.006.

    Article  PubMed  Google Scholar 

  55. • Hozumi H, Enomoto N, Oyama Y, Kono M, Fujisawa T, Inui N, et al. Clinical implication of proteinase-3-antineutrophil cytoplasmic antibody in patients with idiopathic interstitial pneumonias. Lung. 2016;194:235–42. https://doi.org/10.1007/s00408-016-9851-x A study describing the presence of PR3-ANCA in patients labelled as having ILF, and their course. It found more variability on imaging findings that in subjects with ILF, and that no patient evolved to full-blown AAV, as opposed to what occurs in patients with MPO-ANCA positive LF.

  56. • Mohammad AJ, Mortensen KH, Babar J, Smith R, Jones RB, Nakagomi D, et al. Pulmonary involvement in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: the influence of ANCA subtype. J Rheumatol. 2017;44:1458–67. https://doi.org/10.3899/jrheum.161224 This study showed the main distinctive imaging findings in the respiratory system between patients categorized according to their serotype.

  57. • Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75:1583–94. https://doi.org/10.1136/annrheumdis-2016-209133 In summary, the current standard of therapy for the AAV as analyzed with methodological appropriateness.

  58. Kagiyama N, Takayanagi N, Kanauchi T, Ishiguro T, Yanagisawa T, Sugita Y. Antineutrophil cytoplasmic antibody-positive conversion and microscopic polyangiitis development in patients with idiopathic pulmonary fibrosis. BMJ Open Respir Res. 2015;2:e000058. https://doi.org/10.1136/bmjresp-2014-000058.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. New Engl J Med. 2012;366(21):1968–77. https://doi.org/10.1056/NEJMoa1113354.

    Article  Google Scholar 

  60. Richeldi L, Varone F, Bergna M, de Andrade J, Falk J, Halloweel R, et al. Pharmacological management of progressive fibrosing interstitial lung diseases: a review of the current evidence. Eur Respir Rev. 2018;27:180074. https://doi.org/10.1183/16000617.0074-2018.

    Article  PubMed  Google Scholar 

  61. Kondoh Y, Taniguchi H, Yokoi T, Nishiyama O, Ohishi T, Kato T, et al. Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia. Eur Respir J. 2005;5:528–33.

    Article  CAS  Google Scholar 

  62. Tomassetti S, Ryu JH, Piciucchi S, Chilosi M, Poletti V. Nonspecific inerstitial pneumonia: what is the optimal approach to management? Semin Respir Crit Care Med. 2016;37:378–94. https://doi.org/10.1055/s-0036-1583176.

    Article  PubMed  Google Scholar 

  63. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192:e3–19. https://doi.org/10.1164/rccm.201506-1063ST.

    Article  PubMed  Google Scholar 

  64. Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. 2017;20:3–17074. https://doi.org/10.1038/nrdp.2017.74.

    Article  Google Scholar 

  65. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. New Engl J Med. 2014;370(22):2071–82. https://doi.org/10.1056/NEJMoa1402584.

    Article  CAS  PubMed  Google Scholar 

  66. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. New Engl J Med. 2014;370(22):2083–92. https://doi.org/10.1056/NEJMoa1402582.

    Article  CAS  PubMed  Google Scholar 

  67. Cottin V, Koschel D, Günther A, Albera C, Azuma A, Sköld CM, et al. Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study. ERJ Open Res. 2018;4:00084–2018. https://doi.org/10.1183/23120541.00084-2018.

    Article  PubMed  PubMed Central  Google Scholar 

  68. • Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4:708–19. https://doi.org/10.1016/S2213-2600(16)30152-7 In this duble-blind, double-dummy study, mycophenolate mofetil (MMF) and cyclophosphamide were beneficial regarding forced-vital capacity in patients with scleroderma and ILD. Probably, MMF would be preferred due to less toxicity.

  69. Fischer A, Brown KK, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40:640–6. https://doi.org/10.3899/jrheum.121043.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Lederer DJ, Martínez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;378:1811–23. https://doi.org/10.1056/NEJMra1705751.

    Article  CAS  PubMed  Google Scholar 

  71. Jeffs LS, Peh CA, Jose MD, Lange K, Hurtado PR. Randomized trial investigating the safety and efficacy of influenza vaccination in patients with antinuetrophil cytoplasmic antibody-associated vasculitis. Nephrology (Carlton). 2015;20:343–51. https://doi.org/10.1111/nep.12416.

    Article  CAS  Google Scholar 

  72. •• Hozumi H, Oyama Y, Yasui H, Suzuki Y, Kono M, Karayama M, et al. Clinical significance of myeloperoxidase-anti-neutrophil cytoplasmic antibody in idiopathic interstitial pneumonias. PLoS One. 2018;13(6):e0199659. https://doi.org/10.1371/journal.pone.0199659 A relevant study that showed the outcome of patients with MPO-ANCA labelled as ILF. It found that an UIP radiological pattern and no treatment may associate with further development of MPA.

  73. Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015;46:976–87. https://doi.org/10.1183/13993003.00150-2015.

    Article  CAS  PubMed  Google Scholar 

  74. •• Schirmer JH, Wright MN, Vonthein R, Herrmann K, Nölle B, Both M, et al. Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort. Rheumatology. 2016;55:71–9. https://doi.org/10.1093/rheumatology/kev286 This article from one of the largest single-center cohorts of AAV shows that, although mortality was not high, LF is responsible for a somber prognosis when present. It also showed that LF is not uncommon in this ethnic group.

  75. Hirayama K, Kobayashi M, Usui J, Arimura Y, Sugiyama H, Nitta K, et al. Pulmonary involvements of anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis in Japan. Nephrol Dial Transplant. 2015;30:i83–93. https://doi.org/10.1093/ndt/gfu385.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Primary Systemic Vasculitides Clinic, Instituto Nacional de Enfermedades Respiratorias, Calzada de Tlalpan 4502, Col. Sección XVI, CP 14080, Mexico City, Mexico

    Luis Felipe Flores-Suárez MD, PhD & Goethe Sacoto MD

Authors
  1. Luis Felipe Flores-Suárez MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Goethe Sacoto MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luis Felipe Flores-Suárez MD, PhD.

Ethics declarations

Conflict of Interest

Luis Felipe Flores-Suárez Reports lecture/speaker fees from Nippon Boehringer-Ingelheim Co. Ltd.

Goethe Sacoto declares no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Vasculitis

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Flores-Suárez, L.F., Sacoto, G. Interstitial Lung Disease and ANCA-Associated Vasculitis. Curr Treat Options in Rheum 5, 213–229 (2019). https://doi.org/10.1007/s40674-019-00127-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40674-019-00127-9

Keywords

Search

Navigation